Monday, March 30, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A day in the life of patient advocate, Emily Ullrich

Emily Ullrich is a former professor of Communication Arts and Founder of Nairobi Film Institute, a nonprofit organization she created and where she taught filmmaking to college aged youth in Nairobi, Kenya for free. She was sick for many years before she was diagnosed with Interstitial Cystitis, Endometriosis, and Complex Regional Pain Syndrome in 2015, and Ehlers Danlos Syndrome in 2019, and has had to adapt her lifestyle according to her medical issues.

According to a study published in 2019, roughly 70% of patients diagnosed with Ehlers Danlos are women:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858200/#:~:text=We%20found%206021%20individuals%20(men,a%20practice%20of%205000%20patients.

Diagnostic criteria for the disease can be found at the following link:

https://www.ehlers-danlos.com/wp-content/uploads/2017/05/hEDS-Dx-Criteria-checklist-1.pdf

#interstitial #cystitis #endometriosis #CRPS #Ehlers #Danlos

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!